Quantumzyme Patents Advance Sustainable Ibuprofen Manufacturing Process

Quantumzyme Corp. has announced the World Intellectual Property Organization publication of its international patent application covering enzymatic synthesis of ibuprofen, marking a substantial advancement in sustainable pharmaceutical manufacturing. The patent titled "Modified Polypeptides for Enzymatic Synthesis of Ibuprofen" (Publication No. WO 2025/093935 A1) complements the company's previously announced U.S. Patent Application (US 2025/0146029 A1), establishing comprehensive protection for Quantumzyme's proprietary enzyme engineering platform across both domestic and international markets.

This development represents a critical milestone in the company's broader growth strategy focused on expanding enzyme engineering capabilities and strengthening intellectual property assets. The patented biocatalytic method enables ibuprofen production through enzyme-mediated processes designed to significantly reduce chemical waste, eliminate harsh reagents, and enhance overall manufacturing efficiency. According to CEO Naveen Kulkarni, "The publication of our patents both in the USA and internationally mark an important milestone for Quantumzyme. It validates the strength of our enzyme engineering technology and enhances our position for global partnerships focused on greener, more efficient pharmaceutical manufacturing."

The technology builds on Quantumzyme's proprietary QZyme Workbench™ platform, which integrates quantum mechanics, molecular modeling, and AI-driven optimization to design next-generation biocatalysts. This platform underpins multiple enzyme systems the company is developing for sustainable, high-efficiency production of active pharmaceutical ingredients and specialty chemicals. The enzymatic approach could transform pharmaceutical manufacturing by replacing traditional chemical synthesis methods with more environmentally friendly alternatives.

For the global pharmaceutical industry, this advancement addresses growing pressure to adopt greener manufacturing practices while maintaining cost efficiency. The technology's potential to reduce environmental impact aligns with increasing regulatory focus on sustainable production methods across multiple jurisdictions. Pharmaceutical companies facing stricter environmental regulations could benefit from licensing this technology to improve their manufacturing sustainability profiles.

Quantumzyme's next steps include continuing laboratory optimization and scale-up validation of the enzymatic ibuprofen synthesis process, pursuing discussions with global pharmaceutical and contract manufacturing organizations regarding licensing or joint-development frameworks, and filing additional patent applications covering related enzymatic transformations and process improvements. The company maintains its corporate profile at https://www.otcmarkets.com/stock/QTZM and provides updates through its official website at https://www.quantumzymecorp.com.

The broader implications extend beyond ibuprofen production, as successful implementation could establish a template for enzymatic synthesis of other pharmaceuticals. This approach represents a shift toward biocatalysis in an industry traditionally dominated by chemical synthesis methods, potentially reducing the environmental footprint of pharmaceutical manufacturing while maintaining product quality and production scalability.